Development of GPIIb/IIIa antagonists as antithrombotic drugs

Andrew J. Nichols, Robert R. Ruffolo, William F. Huffman, George Poste, James Samanen

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations


Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombosis, namely platelet aggregation, and how it can be inhibited by antagonists of the adhesion molecule GPIIb/IIIa. Successful and future therapeutic applications of GPIIb/IIIa antagonists, and their pharmacology, are considered in detail.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalTrends in Pharmacological Sciences
Issue numberC
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Development of GPIIb/IIIa antagonists as antithrombotic drugs'. Together they form a unique fingerprint.

Cite this